PT - JOURNAL ARTICLE AU - Mittra, Indraneel AU - de Souza, Rosemarie AU - Bhadade, Rakesh AU - Madke, Tushar AU - Shankpal, P.D. AU - Joshi, Mohan AU - Qayyumi, Burhanuddin AU - Bhattacharjee, Atanu AU - Gota, Vikram AU - Gupta, Sudeep AU - Chaturvedi, Pankaj AU - Badwe, Rajendra TI - Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002) AID - 10.1101/2020.07.21.20151423 DP - 2020 Jan 01 TA - medRxiv PG - 2020.07.21.20151423 4099 - http://medrxiv.org/content/early/2020/07/29/2020.07.21.20151423.short 4100 - http://medrxiv.org/content/early/2020/07/29/2020.07.21.20151423.full AB - Background To be universally applicable in treatment of severe COVID-19, novel therapies, especially those with little toxicity and low cost, are urgently needed. We report here the use of one such therapeutic combination involving two commonly used nutraceuticals, namely resveratrol and copper in patients with this disease. This study was prompted by pre-clinical reports that sepsis-related cytokine storm and fatality in mice can be prevented by oral administration of small quantities of resveratrol and copper. Since cytokine storm and sepsis are major causes of death in severe COVID-19, we retrospectively analyzed outcomes of patients with this condition who had received resveratrol and copper.Methods & Findings Our analysis comprised of 230 patients with severe COVID-19 requiring inhaled oxygen who were admitted in a single tertiary care hospital in Mumbai between April 1 and May 13 2020. Thirty of these patients received, in addition to standard care, resveratrol and copper at doses of 5.6 mg and 560 ng, respectively, orally, once every 6 hours, until discharge or death. These doses were based on our pre-clinical studies, and were nearly 50 times and 2000 times less, respectively, than those recommended as health supplements. A multivariable-adjusted analysis was used to model the outcome of death in these patients and evaluate factors associated with this event. A binary logistic regression analysis was used, with age, sex, presence of comorbidities and receipt of resveratrol-copper as covariates. Data were updated as of May 30 2020. The number of deaths in resveratrol-copper and standard care only groups were 7/30 (23.3%, 95% CI 8.1%-38.4%) and 89/200 (44.5%, 95% CI 37.6%-51.3%), respectively. In multivariable analysis, age >50 years [odds ratio (OR) 2.558, 95% CI 1.454-4.302, P=0.0011] and female sex (OR 1.939, 95% CI 1.079-3.482, P=0.0267) were significantly associated, while presence of co-morbidities was not significantly associated (OR 0.713, 95% CI 0.405-1.256, P=0.2421) with death. There was a trend towards reduction in death in patients receiving resveratrol-copper (OR 0.413, 95% CI 0.164-1.039, P= 0.0604).Conclusions We provide preliminary results of a novel approach to the treatment of severe COVID-19 using a combination of small amounts of commonly used nutraceuticals, which is non-toxic and inexpensive, and therefore could be widely accessible globally. The nearly two-fold reduction in mortality with resveratrol-copper observed in our study needs to be confirmed in a randomized controlled trial.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinical Trials Registry of India; Registration Number CTRI/2020/06/026256Clinical Protocols http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45115&EncHid=&userName=Rosemarie%20desouza Funding StatementThis study was supported by the Department of Atomic Energy, Government of India through its grant CTC to Tata Memorial Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational study was approved by the Ethics Committee of BYL Nair Hospital, Mumbai. The study is registered in the Clinical Trials Registry of India; Registration Number CTRI/2020/06/026256. The analysis was conducted adhering to ethical principles, including maintaining patient confidentiality. All authors vouch for the accuracy of data and analysis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified patient data used for analysis in this study is made available as table 2 in the manuscript.